Business Context and Reporting Period
This Form 8-K Current Report was filed by ADVENTRX Pharmaceuticals, Inc. (not Savara Inc.) on May 3, 2010. The filing discloses the entry into a material definitive agreement for a registered direct public offering of securities. The transaction is expected to close on May 6, 2010.
Key Financial Metrics and Transaction Details
- Securities Issued: 19,217.13016 shares of 2.19446320054018% Series F Convertible Preferred Stock and warrants to purchase up to 2,595,156 shares of common stock.
- Unit Structure: Each unit consists of one share of preferred stock, a Series A warrant (approx. 94.53 shares), and a Series B warrant (approx. 40.51 shares).
- Offering Price: $1,000 per unit.
- Total Dilution: An aggregate of 7,785,468 shares of common stock are issuable upon conversion and exercise.
- Net Proceeds: Expected to be approximately $13.4 million after deducting fees, expenses, and dividend obligations.
- Escrow: Approximately 22% of gross proceeds (approx. $4.2 million) will be placed in escrow for dividend and make-whole payments.
- Transaction Fees: Placement agent fee is approximately $1,537,370 (8.0% of gross proceeds), including $201,780 to a non-exclusive financial advisor.
Material Changes and Terms
The filing details the terms of the new Series F Convertible Preferred Stock and associated warrants:
- Conversion Price: Effective conversion price of $3.7025 per share of common stock.
- Dividend: Accrues at 2.19446320054018% until May 6, 2020. If converted early, holders receive accrued dividends (approx. $219.45 per $1,000 stated value).
- Warrant Exercise Prices: Both Series A and Series B warrants have an exercise price of $3.65 per share.
- Warrant Expiration: Series A warrants expire 5 years after issuance; Series B warrants expire 10 trading days after the 1-year anniversary.
- Covenants: The agreement restricts the Company from amending its charter, paying cash dividends on common stock, repurchasing shares, issuing additional equity for 90 days, or incurring indebtedness without consent.
Outlook, Risks, and Contingencies
The transaction is subject to customary closing conditions. The filing notes that the convertible preferred stock is subject to automatic conversion upon a change in control. The Company may be obligated to redeem the stock upon material breach of contract, change in control, insolvency events, or delisting of common stock. The filing does not provide specific revenue, profit, or cash flow metrics for the reporting period, as this is a transactional filing rather than a periodic financial report.
Investor Verification Checklist
- Verify the closing of the transaction on or around May 6, 2010.
- Confirm the actual net proceeds received versus the estimated $13.4 million.
- Monitor the Company's ability to maintain the listing of its common stock on specified exchanges as required by the covenants.
- Review the impact of the 7,785,468 potentially issuable shares on existing shareholder dilution.
- Check for any subsequent filings regarding the release of funds from the $4.2 million escrow account.